BioSpace News Archive

Immunocore Holdings plc will present Phase 1 expansion data for brenetafusp, the first off-the-shelf ImmTAC therapy targeting PRAME, in patients with late-line cutaneous melanoma, all previously treated with anti-PD1 and the vast majority having received ipilimumab, at the 2024 American Society of Oncology Annual Meeting commencing on 31 May.

Werewolf Therapeutics, Inc. announced that an abstract providing an update of the Company’s ongoing monotherapy and combination Phase 1/1b study of WTX-124, its interleukin 2 INDUKINE™ molecule, has been accepted for poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 - June 4 in Chicago, Illinois.

Coherus BioSciences, Inc. announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago.

Agenus Inc. announced an upcoming presentation from the Phase 1b trial of botensilimab in combination with balstilimab in patients with relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases will be presented at the upcoming American Society of Clinical Oncology Meeting, to be held May 31 – June 4, 2024, in Chicago, IL.

SOTIO Biotech announced it will present a Trial-in-Progress poster on the DUET-01 Phase 1/2 study of BOXR1030 at the 2024 American Society of Clinical Oncology Annual Meeting taking place May 31 – June 4, 2024, in Chicago, IL.

Bicycle Therapeutics plc announced the acceptance of two abstracts for poster presentation at the 2024 American Society for Clinical Oncology Annual Meeting, taking place May 31-June 4 in Chicago.

Obsidian Therapeutics, Inc. announced two presentations, including an oral presentation on the Phase 1 first-in-human study of OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy armored with pharmacologically regulatable membrane-bound IL15, in patients with immune checkpoint inhibitor -resistant advanced or metastatic melanoma, at the 2024 American Society of Clinical Oncology Annual Meeting, taking place in Chicago on May 31–June 4.

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that updated Phase 1/2 data for AU-007 will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.

Last week Exergen Corporation filed a lawsuit against Baxter International Inc. in the United States District Court for the District of Massachusetts.

Blue Arbor Technologies Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the RESTORE™ Neuromuscular Interface System for people with upper limb loss.